AB SCIENCE news, videos and press releases
For more news please use our advanced search feature.
AB SCIENCE - More news...
AB SCIENCE - More news...
- AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
- AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
- AB Science announces EMA approval of Masivet shelf-life extension to 4 years
- AB Science announces the successful completion of a EUR 1.8 million private placement
- AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib
- AB Science reports its revenues for the year 2024 and provides an update on its activities
- AB Science will publish its 2024 annual financial report on May 9, 2025
- AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
- AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
- AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
- AB Science announces a slight delay in the publication of its 2024 half-year financial report
- AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
- AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
- AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
- AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
- AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
- AB Science reports its revenues for the year 2023 and provides an update on its activities
- AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036
- AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
- AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
- AB Science announces a slight delay in the publication of its 2023 annual financial report
- AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
- AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
- AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
- AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
- AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
- AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
- AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
- AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
- AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting
